Paediatric HIV-1 infection

Lancet

Volumn 354, Issue SUPPL.2, 1999, Pages

  Burns, David N ^a   Mofenson, Lynne M ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BREAST FEEDING; CESAREAN SECTION; CHILD; CLINICAL TRIALS; DISEASE TRANSMISSION, VERTICAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MILK, HUMAN; PREGNANCY; WORLD HEALTH; ZIDOVUDINE;

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; ZIDOVUDINE;

CESAREAN SECTION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; NEWBORN; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; THAILAND; UGANDA; UNITED STATES; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 0032873156     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)90249-0     Document Type: Article

References (60)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80.
2. Lindegren ML, Byers RH, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999; 282: 531-38.
3. Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998; 280: 55-60.
4. The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353: 1035-39.
5. The International Perinatal HIV Group. Mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340: 977-87.
6. Joint United Nations Programme on HIV/AIDS (UNAIDS). 1999 World AIDS campaign: facts and figures. Geneva UNAIDS, 1999. (http://www.unaids.org/unaids/highband/events/wad/1999/index.html; accessed Aug 2, 1999).
7. Zijenah L, Mbizvo MT, Kasule J, et al. Mortality in the first 2 years among infants born to human immunodeficiency virus-infected women in Harare, Zimbabwe. J Infect Dis 1998; 178: 109-13.
8. Mofenson LM. Short-course zidovudine for prevention of perinatal transmission. Lancet 1999; 353: 766-67.
9. Newell M-L, Dabis F, Tolley K, Whynes D, for the Ghent International Working Group on Mother-to-Child Transmission of HIV. Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. AIDS 1998; 12: 1571-80.
10. Wilkinson D, Floyd K, Gilks CF. Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity. AIDS 1998; 12: 1675-82.
11. Guay A, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVET 012 randomised trial. Lancet 1999; 354: 795-802.
12. Centers for Disease Control and Prevention. Success in implementing Public Health Service guidelines to reduce perinatal transmission of HIV - Louisiana, Michigan, New Jersey and South Carolina, 1993, 1995, 1996. MMWR 1998; 47: 688-91.
13. Shaffer N, Chuachoowong R, Mott PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353: 773-80.
14. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999; 353: 781-85.
15. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999; 353: 786-92.
16. Saba J, on behalf of the PETRA Trial Study Team. Interim analysis of early efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1: the PETRA trial. 6th Conference on Retroviruses and Opportunistic Infections (Chicago, Jan 31-Feb 4, 1999) (abstr S7).
17. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1409.
18. Wade NA, Birkhead GS, French PT. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med 1999; 340: 1042-43.
19. Sperling RS, Shapiro DE, Coombs FW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335: 1621-29.
20. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys, J Natl Cancer Inst 1997; 89: 1602-08.
21. Scalfaro P, Chesaux JJ, Buchwalder PA, Biollaz J, Micheli JL. Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment, Intens Care Med 1998; 24: 247-50.
22. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trials Group ′076 study. AIDS 1998; 12: 1805-13.
23. Culnane MS, Fowler MG, Lee SS, et al. Lack of long-term effect of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 1999; 281: 151-57.
24. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal-neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Human Retrovir 1999; 20: 463-67.
25. Semprini AE, Castagna C, Ravizza M, et al. The incidence of complications after cesarean delivery in 156 HIV-positive women. AIDS 1995; 9: 913-17.
26. Scholl TO, Hediger ML, Bendich A, Schall J, Smith WK, Krueger PM. Use of multivitamin/mineral supplements: influence on the outcome of pregnancy. Am J Epidemiol 1997; 146: 134-41.
27. Rouse DJ, Hauth JC, Andrews WWW, Mills BB, Maher JE. Chlorhexidine vaginal irrigation for the prevention of peripartal infection: a placebo-controlled randomised clinical trial. Am J Obstet Gynecol 1997; 176: 617-22.
28. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune globulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 1999; 179: 567-75.
29. Semba R. Nutritional interventions: vitamin A and breastfeeding. Presented at III International Symposium: on Global Strategies to Prevent Perinatal HIV Transmission (Valencia, Spain, Nov 9-10, 1998).
30. Fawzi WW, Msamanga GI, Spiegelman D, et al. Randomised trial of effects of vitamin supplementation on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Lancet 1998; 351: 1477-82.
31. Biggar RJ, Miotti PG, Taha TE, et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996; 347: 1647-50.
32. Taha TE, Biggar RJ, Broadhead RL, et al. Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial. BMJ 1997; 315: 216-19.
33. Ladner J, Leroy V, Hoffman P, et al. Chorioamnionitis and pregnancy outcome in HIV-infected African women. J Acquir Immune Defic Syndr Hum Retrovir 1998; 18: 293-98.
34. Van Dyke RB, Korber BT, Popek E, et al. The Ariel Project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis 1999; 179: 319-28.
35. Southern SO. Milk-borne transmission of HIV. J Human Virol 1998; 1: 328-37.
36. Lewis P, Nduati R, Kreiss JK, et al. Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis 1998; 177: 34-9.
37. Leroy V, Newell M-L, Dabis F, et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Lancet 1998; 352: 597-600.
38. Coutsoudis A, Pillay K, Spooner F, et al. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. Lancet 1999; 354: 471-76.
39. Foster S, Buve A. Benefits of HIV screening of blood transfusions in Zambia. Lancet 1995; 346: 225-27.
40. Lackritz EM. Prevention of HIV transmission by blood transfusion in the developing world: achievements and continuing challenges. AIDS 1998;12(suppl A): S81-6.
41. Aylward B, Kane M, McNair-Scott R, Hu DJ. Model-based estimates of the risk of human immunodeficiency virus and hepatitis B virus transmission through unsafe injections. Int J Epidemiol 1995; 24: 446-52.
42. World Health Organization. Safety of injections: WHO-UNICEF policy statement for mass immunization campaigns. Wkly Epidemiol Rec 1998; 73: 394.
43. Stanton BF, Li X, Kahihuata J, et al. Increased protected sex and abstinence among Namibian youth following an HIV risk-reduction intervention: a randomised, longitudinal study. AIDS 1998; 12: 2473-80.
44. Jemmott JB 3rd, Jemmott LS, Fong GT. Abstinence and safer sex HIV risk-reduction interventions for African American adolescents: a randomised controlled trial. JAMA 1998; 279: 1529-36.
45. Kilian AHD, Gregson S, Ndyanabangi B, et al. Reductions in risk behaviour provide the most consistent explanation for declining HIV-1 prevalence in Uganda. AIDS 1999; 13: 391-98.
46. Abrams EJ, Weedon J, Steketee RW, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. J Infect Dis 1998; 178: 101-08.
47. Luzuriaga K, Wu H, McManus M, et al. Dynamics of HIV-1 replication in vertically-infected infants. J Virol 1999; 73: 362-7.
48. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387: 188-91.
49. Nahmias AJ, Clark WS, Kourtis AP, et al. Thymic dysfunction and time of infection predict mortality in human immunodeficiency virus-infected infants. J Infect Dis 1998; 178: 680-85.
50. Uittenbogaart CH, Anisman DJ, Jamieson BD, Kitchen S, Schmid I, Zack JA, Hays EF. Differential tropism of HIV-1 isolates for distinct thymocyte subsets in vitro. AIDS 1996; 10: F9-16.
51. McCune JM, Loftus R, Schmidt DK, et al. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 1998; 101: 2301-08.
52. McFarland EJ, Harding PA, Mawhinney S, Kuritzkes DR, Kotzin BL. Analysis of the T cell receptor (TCR) repertoire in HIV-infected children treated with antiretroviral therapy. Presented at 6th Conference on Retroviruses and Opportunistic Infection (Chicago, 1999) (abstr 319).
53. Cohen Stuart JW, Slieker WA, Rijkers GT, et al. Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. AIDS 1998; 12: 2155-59.
54. McKinney RE, Johnson GM, Stanley K, et al. A randomised study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. J Pediat 1998; 133: 500-08.
55. Yogev R, Stanley K, Nachman SA, et al. Virologic efficacy of ZDV + 3TC vs d4T + ritonavir (RTN) vs ZDV + 3TC + RTN in stable antiretroviral-experienced children (Pediatric AIDS Clinical Trial 338). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, Sept 28-Oct 1, 1997) (abstr LB-6).
56. Starr SE, Fletcher C, Spector SA, et al. Efavirenz in combination with nelfinavir and nucleoside reverse transcriptase inhibitors (NRTIs) is safe and virologically effective in HIV-infected children. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego, Sept 24-27, 1998) (abstr LB-6).
57. Luzuriaga K, McManus M, Britto P, et al. Early combination antiretroviral therapy of vertical HIV-1 infection: viral kinetics and control of viral replication. Fifth Conference on Retroviruses and Opportunistic Infections (Chicago, Feb 1-5, 1998) (abstr LB-12).
58. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998; 47 (RR-4): 1-43.
59. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HTV-1-infected children. J Infect Dis 1997; 175: 1029-38.
60. Palumbo PE, Raskino C, Fiscus S, et al. Virologic and immunologic responses to nucleoside reverse transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children. J Infect Dis 1999; 179: 576-83.